Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.02 USD | +2.87% | +0.20% | +15.94% |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- The company has a low valuation given the cash flows generated by its activity.
- For several months, analysts have been revising their EPS estimates roughly upwards.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- With a 2024 P/E ratio at 19.43 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+15.94% | 242M | C+ | ||
+1.51% | 42.75B | B | ||
+49.22% | 41.61B | A | ||
+8.57% | 41.34B | B- | ||
-12.36% | 26.59B | C | ||
+8.92% | 25.49B | B- | ||
-25.13% | 18.12B | B | ||
+29.17% | 12.24B | C+ | ||
-3.12% | 11.76B | C+ | ||
+6.35% | 11B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- PBYI Stock
- Ratings Puma Biotechnology, Inc.